These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22465063)

  • 41. Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo.
    Roviezzo F; Brancaleone V; De Gruttola L; Vellecco V; Bucci M; D'Agostino B; Cooper D; Sorrentino R; Perretti M; Cirino G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):830-7. PubMed ID: 21421740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
    Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling the Effect of the Selective S1P
    Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T
    Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
    Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
    Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
    Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M
    Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ponesimod, a selective sphingosine 1-phosphate (S1P
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 May; 48(5):442-451. PubMed ID: 28489480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.
    van Oosten BW; Rep MH; van Lier RA; Scholten PE; von Blomberg BM; Pflughaupt KW; Hartung HP; Adèr HJ; Polman CH
    J Neuroimmunol; 1996 May; 66(1-2):49-55. PubMed ID: 8964913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects.
    Hwang I; Lee SW; Oh J; Lee S; Jang IJ; Yu KS
    Front Pharmacol; 2022; 13():930615. PubMed ID: 36071831
    [No Abstract]   [Full Text] [Related]  

  • 50. [A systematic study of the significance of lipoids in blood coagulation. II. The effect of the diaminophosphatides and their degradation product sphingosine].
    HECHT E
    Acta Haematol; 1953 Apr; 9(4):237-52. PubMed ID: 13064995
    [No Abstract]   [Full Text] [Related]  

  • 51. Sphingosine as an inhibitor of blood clotting.
    HECHT E; SHAPIRO D
    Science; 1957 May; 125(3256):1041-2. PubMed ID: 13432756
    [No Abstract]   [Full Text] [Related]  

  • 52. Purification and properties of sphingosine.
    BRADY RO; BURTON RM
    J Neurochem; 1956 May; 1(1):18-21. PubMed ID: 13346370
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
    JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
    Vollmer TL; Sorensen PS; Selmaj K; Zipp F; Havrdova E; Cohen JA; Sasson N; Gilgun-Sherki Y; Arnold DL;
    J Neurol; 2014 Apr; 261(4):773-83. PubMed ID: 24535134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
    Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abatacept for Crohn's disease and ulcerative colitis.
    Sandborn WJ; Colombel JF; Sands BE; Rutgeerts P; Targan SR; Panaccione R; Bressler B; Geboes K; Schreiber S; Aranda R; Gujrathi S; Luo A; Peng Y; Salter-Cid L; Hanauer SB
    Gastroenterology; 2012 Jul; 143(1):62-69.e4. PubMed ID: 22504093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.
    Khan SA; Goliwas KF; Deshane JS
    Front Physiol; 2021; 12():760638. PubMed ID: 34690821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.